RECEIVED
CENTRAL FAX CENTER
SEP 2 4 2007

Application Number: 10/602,456
Balschmidt et al.
Filed: June 23, 2003
Attorney Docket No.: 6460.200-US
Via Facsimile No.: 571-273-8300

AMENDMENTS TO THE CLAIMS

CLAIM LISTING

1. (**Currently amended**) A pharmaceutical composition **, wherein the pharmaceutical composition comprises** ~~**comprising**~~ a peptide and one or more isotonicity agents **that act to provide tonicity or osmolarity close to that of the body fluids at the administration site,** wherein at least one of the isotonicity agents is dimethyl sulfone, wherein the concentration of dimethyl sulfone is from 40 to 400 mM, wherein the peptide is selected from human growth hormone, GLP-1, GLP-2, insulin, Factor VIIa, Factor VIII, erythropoietin (EPO), glucagon, interleukin-2 (IL-2), interferon-α, and interferon-β, an analog of the peptide, a derivative of the peptide, or **a** derivative of the analog of the peptide **thereof**, and wherein the pharmaceutical composition is administered parenteraly to a subject in need thereof.

2. (Cancelled)

3. (Previously presented) **The** **[[A]]** pharmaceutical composition according to claim 1, wherein the concentration of dimethyl sulfone is from 125 to 350 mM.

4. (Original) **The** **[[A]]** pharmaceutical composition according to claim 1, wherein the composition is a solution.

5. (Original) **The** [[A]] pharmaceutical composition according to claim 1, wherein the composition is a suspension.

6. (**Currently amended**) **The** **[[A]]** pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is **formulated for administration** ~~**administered**~~ by injection or infusion to a subject in need thereof.

7. (Previously presented) **The** **[[A]]** pharmaceutical composition according to claim 6, wherein the pharmaceutical composition is **formulated for administration** ~~**administered**~~ subcutaneously to a subject in need thereof.

8. (Previously presented) **The** **[[A]]** pharmaceutical composition according to claim 6, wherein the pharmaceutical composition is **formulated for administration** ~~**administered**~~ intramuscularly to a subject in need thereof.

9. (Previously presented) **The** **[[A]]** pharmaceutical composition according to claim 6, wherein the pharmaceutical composition is **formulated for administration** ~~**administered**~~ intravenously to a subject in need thereof.

10. (Previously presented) **The** **[[A]]** pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is **formulated for administration** ~~**administered**~~ pulmonaly to a subject in need thereof.

11. (Previously presented) **The** **[[A]]** pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is **formulated for administration** ~~**administered**~~ opthalmically or topically to a subject in need thereof.

12. (Cancelled)

13. (Previously presented) **The** **[[A]]** pharmaceutical composition according to claim 1, wherein the peptide is selected from human insulin, a derivative of human insulin, an analogue of human insulin, or a derivative of an analogue of human insulin.

14. (Original) **The** **[[A]]** pharmaceutical composition according to claim 13, wherein the peptide is human insulin.

15. (Original) The [[A]] pharmaceutical composition according to claim 13, wherein the peptide is Asp(B28)-human insulin.

16. (Original) The [[A]] pharmaceutical composition according to claim 13, wherein the peptide is Lys(B28) Pro(B29)-human insulin.

17. (Original) The [[A]] pharmaceutical composition according to claim 13, wherein the peptide is Lys(B3) Glu(B29)-human insulin.

18. (Original) The [[A]] pharmaceutical composition according to claim 13, wherein the peptide is $N^{\varepsilon B29}$-tetradecanoyl des (B30)-human insulin.

19. (Original) The [[A]] pharmaceutical composition according to claim 13, wherein the peptide is Gly(A21) Arg(B31) Arg(B32)-human insulin.

20. (Previously presented) The [[A]] pharmaceutical composition according to claim 13, wherein the peptide is $N^{\varepsilon B29}$–lithocholoyl-γ-glutamyl des (B30)-human insulin.

21. (Previously presented) The [[A]] pharmaceutical composition according to claim 1, wherein the peptide is Gly(8)-human GLP-1.

22. (Previously presented) The [[A]] pharmaceutical composition according to claim 1, wherein the peptide is Arg(34), N-ε-(γ-Glu(N-α-hexadecanoyl))-Lys(26)-human GLP-1(7-37)OH.

23. (Previously presented) The [[A]] pharmaceutical composition according to claim 1, wherein the peptide is Gly(2)-human GLP-2.